The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial.
Chronic kidney disease
Hyperuricemia
Renal function
Uric acid
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
04
04
2019
accepted:
13
12
2019
pubmed:
27
12
2019
medline:
5
2
2021
entrez:
27
12
2019
Statut:
ppublish
Résumé
The influence of uric acid (UA) on renal function and the significance of UA-lowering therapy are unclear. The purpose of the sub-analysis of the Assessment of Clinical Usefulness in chronic kidney disease patients with Atorvastatin (ASUCA) trial was to evaluate the influence of serum UA levels on renal function in Japanese chronic kidney disease patients with hyperlipidemia. Of 344 participants in the ASUCA trial, 279 participants whose UA levels at both baseline and 24 months were available were included. Based on UA level at baseline or mean UA level during the trial period, they were divided into four groups: < 5.0, 5.0-6.0, 6.0-7.0, or ≥ 7.0 mg/dL, irrespective of allocation. Changes in the estimated glomerular filtration rate (eGFR) after 24 months were compared among the groups in relation to baseline or mean UA levels. For baseline UA levels (< 5.0, 5.0-6.0, 6.0-7.0, or ≥ 7.0 mg/dL), the change in eGFR after 24 months was - 1.32 ± 10.3, - 1.74 ± 8.94, - 2.53 ± 7.34, and - 3.51 ± 9.10 mL/min/1.73 m In CKD patients with dyslipidemia, hyperuricemia was an independent risk factor for CKD progression. An ongoing clinical trial (TARGET-UA, UMIN-ID 000,026,741) may reveal the significance of strict UA-lowering therapy in CKD patients.
Sections du résumé
BACKGROUND
BACKGROUND
The influence of uric acid (UA) on renal function and the significance of UA-lowering therapy are unclear. The purpose of the sub-analysis of the Assessment of Clinical Usefulness in chronic kidney disease patients with Atorvastatin (ASUCA) trial was to evaluate the influence of serum UA levels on renal function in Japanese chronic kidney disease patients with hyperlipidemia.
METHODS
METHODS
Of 344 participants in the ASUCA trial, 279 participants whose UA levels at both baseline and 24 months were available were included. Based on UA level at baseline or mean UA level during the trial period, they were divided into four groups: < 5.0, 5.0-6.0, 6.0-7.0, or ≥ 7.0 mg/dL, irrespective of allocation. Changes in the estimated glomerular filtration rate (eGFR) after 24 months were compared among the groups in relation to baseline or mean UA levels.
RESULTS
RESULTS
For baseline UA levels (< 5.0, 5.0-6.0, 6.0-7.0, or ≥ 7.0 mg/dL), the change in eGFR after 24 months was - 1.32 ± 10.3, - 1.74 ± 8.94, - 2.53 ± 7.34, and - 3.51 ± 9.10 mL/min/1.73 m
CONCLUSION
CONCLUSIONS
In CKD patients with dyslipidemia, hyperuricemia was an independent risk factor for CKD progression. An ongoing clinical trial (TARGET-UA, UMIN-ID 000,026,741) may reveal the significance of strict UA-lowering therapy in CKD patients.
Identifiants
pubmed: 31875936
doi: 10.1007/s10157-019-01840-4
pii: 10.1007/s10157-019-01840-4
pmc: PMC7174259
doi:
Substances chimiques
Anticholesteremic Agents
0
Uric Acid
268B43MJ25
Atorvastatin
A0JWA85V8F
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
420-426Références
Indian J Dermatol. 2011 May;56(3):278-81
pubmed: 21772587
Clin J Am Soc Nephrol. 2010 Aug;5(8):1388-93
pubmed: 20538833
Am J Kidney Dis. 2004 Oct;44(4):642-50
pubmed: 15384015
Clin Exp Nephrol. 2017 Jun;21(3):417-424
pubmed: 27392909
Adv Chronic Kidney Dis. 2012 Nov;19(6):377-85
pubmed: 23089272
Diabetes. 2009 Jul;58(7):1668-71
pubmed: 19411615
Am J Physiol Renal Physiol. 2006 Mar;290(3):F625-31
pubmed: 16234313
BMC Neurol. 2015 Feb 28;15:16
pubmed: 25884318
Am J Kidney Dis. 1999 Feb;33(2):225-34
pubmed: 10023633
PLoS One. 2011;6(11):e27817
pubmed: 22125626
Am J Physiol Renal Physiol. 2013 Mar 1;304(5):F471-80
pubmed: 23283992
Am J Kidney Dis. 2006 Jan;47(1):51-9
pubmed: 16377385
Nephrol Dial Transplant. 2013 Sep;28(9):2221-8
pubmed: 23543594
Am J Nephrol. 2003 Jan-Feb;23(1):2-7
pubmed: 12373074
Am J Nephrol. 2007;27(5):435-40
pubmed: 17622758
Hypertension. 2001 Nov;38(5):1101-6
pubmed: 11711505
Acta Diabetol. 2016 Aug;53(4):599-607
pubmed: 26935413
Exp Gerontol. 2008 Apr;43(4):347-52
pubmed: 18294794
Am J Kidney Dis. 2010 Aug;56(2):264-72
pubmed: 20385436
Am J Physiol Renal Physiol. 2008 Oct;295(4):F1134-41
pubmed: 18701632
J Am Soc Nephrol. 2002 Dec;13(12):2888-97
pubmed: 12444207
Clin Exp Nephrol. 2013 Apr;17(2):211-7
pubmed: 22948416
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Kidney Int. 2005 Jan;67(1):237-47
pubmed: 15610247
Am J Kidney Dis. 2009 May;53(5):796-803
pubmed: 19303683
Am J Physiol Renal Physiol. 2007 Apr;292(4):F1238-44
pubmed: 17190912
Am J Med. 1982 Jan;72(1):95-100
pubmed: 7058827